Suppr超能文献

滑动剂量人绒毛膜促性腺激素扳机法产生等效的妊娠结局并降低卵巢过度刺激综合征:对10427个体外受精-卵胞浆内单精子注射周期的分析。

Sliding scale HCG trigger yields equivalent pregnancy outcomes and reduces ovarian hyperstimulation syndrome: Analysis of 10,427 IVF-ICSI cycles.

作者信息

Gunnala Vinay, Melnick Alexis, Irani Mohamad, Reichman David, Schattman Glenn, Davis Owen, Rosenwaks Zev

机构信息

The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, New York, United States of America.

出版信息

PLoS One. 2017 Apr 25;12(4):e0176019. doi: 10.1371/journal.pone.0176019. eCollection 2017.

Abstract

OBJECTIVE

To evaluate pregnancy outcomes and the incidence of ovarian hyperstimulation syndrome (OHSS) using a sliding scale hCG protocol to trigger oocyte maturity and establish a threshold level of serum b-hCG associated with optimal oocyte maturity.

DESIGN

Retrospective cohort.

SETTING

Academic medical center.

PATIENTS

Fresh IVF cycles from 9/2004-12/2011.

INTERVENTION

10,427 fresh IVF-ICSI cycles met inclusion criteria. hCG was administered according to E2 level at trigger: 10,000IU vs. 5,000IU vs. 4,000IU vs. 3,300IU vs. dual trigger (2mg leuprolide acetate + 1,500IU hCG). Serum absorption of hCG was assessed according to dose and BMI.

MAIN OUTCOME MEASURES

Oocyte maturity was analyzed according to post-trigger serum b-hCG. Fertilization, clinical pregnancy, live birth and OHSS rates were examined by hCG trigger dose.

RESULTS

Post-trigger serum b-hCG 20-30, 30-40, and 40-50 mIU/mL was associated with reduced oocyte maturity as compared b-hCG >50 (67.8% vs. 71.4% vs. 73.3% vs. 78.9%, respectively, P<0.05). b-hCG 20-50 mIU/mL was associated with a 40.1% reduction in live birth (OR 0.59, 95% CI 0.41-0.87). No differences in IVF outcomes per retrieval were seen for varying doses of hCG or dual trigger when controlling for patient age. The incidence of moderate to severe OHSS was 0.13% (n = 14) and severe OHSS was 0.03% (n = 4) of cycles.

CONCLUSIONS

Moderate stimulation with sliding scale hCG at trigger and fresh transfer is associated with low rates of OHSS and favorable pregnancy rates. Doses as low as 3,300IU alone or dual trigger with 1,500IU are sufficient to facilitate oocyte maturity.

摘要

目的

采用hCG剂量递减方案诱导卵母细胞成熟,评估妊娠结局及卵巢过度刺激综合征(OHSS)的发生率,并确定与最佳卵母细胞成熟相关的血清β-hCG阈值水平。

设计

回顾性队列研究。

地点

学术医疗中心。

患者

2004年9月至2011年12月的新鲜体外受精周期。

干预措施

10427个新鲜体外受精-卵胞浆内单精子注射(IVF-ICSI)周期符合纳入标准。根据触发时的雌二醇(E2)水平给予hCG:10000IU对比5000IU对比4000IU对比3300IU对比双重触发(2mg醋酸亮丙瑞林+1500IU hCG)。根据剂量和体重指数(BMI)评估hCG的血清吸收情况。

主要观察指标

根据触发后血清β-hCG分析卵母细胞成熟情况。通过hCG触发剂量检查受精、临床妊娠、活产和OHSS发生率。

结果

与β-hCG>50 mIU/mL相比,触发后血清β-hCG 20 - 30、30 - 40和40 - 50 mIU/mL时卵母细胞成熟率降低(分别为67.8%对比71.4%对比73.3%对比78.9%,P<0.05)。β-hCG 20 - 50 mIU/mL与活产率降低40.1%相关(比值比[OR]0.59,95%置信区间[CI]0.41 - 0.87)。在控制患者年龄时,不同剂量的hCG或双重触发在每次取卵的体外受精结局方面未见差异。中度至重度OHSS的发生率为周期数的0.13%(n = 14),重度OHSS为0.03%(n = 4)。

结论

触发时采用hCG剂量递减方案进行适度刺激并新鲜移植,与低OHSS发生率和良好的妊娠率相关。低至3300IU单独使用或与1500IU双重触发足以促进卵母细胞成熟。

相似文献

2
Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
Cochrane Database Syst Rev. 2014 Oct 31;2014(10):CD008046. doi: 10.1002/14651858.CD008046.pub4.
3
GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.
J Obstet Gynaecol. 2020 Aug;40(6):837-842. doi: 10.1080/01443615.2019.1674262. Epub 2019 Dec 3.
5
Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Cochrane Database Syst Rev. 2011 Jan 19(1):CD008046. doi: 10.1002/14651858.CD008046.pub3.
6
Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Cochrane Database Syst Rev. 2010 Nov 10(11):CD008046. doi: 10.1002/14651858.CD008046.pub2.

引用本文的文献

3
Prediction, assessment, and management of suboptimal GnRH agonist trigger: a systematic review.
J Assist Reprod Genet. 2022 Feb;39(2):291-303. doi: 10.1007/s10815-021-02359-y. Epub 2022 Mar 19.
4
Gonadotropin levels at the start of ovarian stimulation predict normal fertilization after hCG re-trigger in GnRH antagonist cycles.
Reprod Med Biol. 2020 Dec 18;20(1):96-107. doi: 10.1002/rmb2.12359. eCollection 2021 Jan.
6
The rate of euploid miscarriage is increased in the setting of adenomyosis.
Hum Reprod Open. 2018 Jul 4;2018(3):hoy011. doi: 10.1093/hropen/hoy011. eCollection 2018.
8
Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.
Endocr Rev. 2018 Oct 1;39(5):593-628. doi: 10.1210/er.2017-00236.

本文引用的文献

1
Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles.
Fertil Steril. 2015 Sep;104(3):637-42. doi: 10.1016/j.fertnstert.2015.06.011. Epub 2015 Jul 3.
2
Prevention of Ovarian Hyperstimulation Syndrome: A Review.
Obstet Gynecol Int. 2015;2015:514159. doi: 10.1155/2015/514159. Epub 2015 May 14.
3
Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention.
Ultrasound Obstet Gynecol. 2015 Apr;45(4):377-93. doi: 10.1002/uog.14684. Epub 2015 Mar 1.
4
Is severe OHSS associated with adverse pregnancy outcomes? Evidence from a case-control study.
Reprod Biomed Online. 2014 Aug;29(2):216-21. doi: 10.1016/j.rbmo.2014.04.015. Epub 2014 May 15.
5
GnRH antagonist-based protocols for in vitro fertilization.
Methods Mol Biol. 2014;1154:289-304. doi: 10.1007/978-1-4939-0659-8_13.
6
Assisted reproductive techniques.
Methods Mol Biol. 2014;1154:171-231. doi: 10.1007/978-1-4939-0659-8_8.
7
Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma.
J Ovarian Res. 2013 Nov 5;6(1):77. doi: 10.1186/1757-2215-6-77.
8
Triggering final oocyte maturation with reduced doses of hCG in IVF/ICSI: a prospective, randomized and controlled study.
Eur J Obstet Gynecol Reprod Biol. 2011 Nov;159(1):143-7. doi: 10.1016/j.ejogrb.2011.07.009. Epub 2011 Aug 6.
9
GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
Hum Reprod Update. 2011 Jul-Aug;17(4):510-24. doi: 10.1093/humupd/dmr008. Epub 2011 Mar 30.
10
Ovarian hyperstimulation syndrome prevention strategies: reducing the human chorionic gonadotropin trigger dose.
Semin Reprod Med. 2010 Nov;28(6):475-85. doi: 10.1055/s-0030-1265674. Epub 2010 Nov 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验